Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature

Novel targeted therapies improve the survival of specific subgroups (defined by genetic variants) of patients with acute myeloid leukemia (AML), validating the paradigm of molecularly targeted therapy. However, identifying correlations between AML molecular attributes and effective therapies is chal...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavor, Sigal, Shalit, Tali, Ilani, Noa Chapal, Moskovitz, Yoni, Livnat, Nir, Groner, Yoram, Barr, Haim, Minden, Mark D., Plotnikov, Alexander, Deininger, Michael W., Kaushansky, Nathali, Shlush, Liran I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726833/
https://www.ncbi.nlm.nih.gov/pubmed/33256378
http://dx.doi.org/10.3324/haematol.2019.240705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726833/
https://www.ncbi.nlm.nih.gov/pubmed/33256378
http://dx.doi.org/10.3324/haematol.2019.240705

Ejemplares similares